LumiThera Named Most Innovative And Promising Medtech & E-Health Company At Biovision 2017

The LT-300 LED ophthalmologic instrument station provides a multi-wavelength approach to treating ocular disease.LumiThera┬« Inc., a clinical stage medical device company focused on delivering non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced it has been awarded the prestigious “MOST INNOVATIVE AND PROMISING MEDTECH & E-HEALTH COMPANY” during Biovision 2017 in Lyon, France.

This is great news for patients suffering from dry AMD who have no other treatment alternatives!

Read the full press release:
LumiThera Named Most Innovative And Promising Medtech & E-Health Company At Biovision 2017

Disclosure: I am an investor in Lumithera a) because it successfully treats an unmet medical need, (dry AMD) b) I think it will be the first billion dollar photobiomodulation company.

About James Carroll

Founder and CEO at THOR Photomedicine Ltd.
View biography (PDF)

This entry was posted in Industry. Bookmark the permalink.

2 Responses to LumiThera Named Most Innovative And Promising Medtech & E-Health Company At Biovision 2017

  1. Lisa Meyer says:

    This is outstanding. Has there been any research into the effectiveness of treating ocular toxoplasmosis with photobiomodulation?

Leave a Reply

Your email address will not be published. Required fields are marked *